NPLEx Brings A ‘Quiet’ Year On State PSE Legislation – CHPA
This article was originally published in The Tan Sheet
Executive Summary
CHPA President and CEO Scott Melville says 2015 is the “quietest” in five years for state legislation on the sale of pseudoephedrine, a testament to NPLEx. Bills for Rx-only PSE sales introduced in four states this year failed.
You may also be interested in...
Pseudoephedrine Tide Turns: Nonprescription Sales Return In Mississippi, Oregon Mulls Change
Mississippi repeals prescription requirement for all pseudoephedrine- and ephedrine-containing drugs while also requiring retailer participation in industry-funded technology for tracking drug sales. Oregon, the only other state with PSE Rx law, is considering repealing it.
States With Age Restriction On OTC DXM Sales Number 17 – And Counting
Pennsylvania is 17th US state to limit sales of dextromethorphan OTCs to consumers 18 and older because teenagers' abuse of the ingredient for intoxicating effect remains a common problem.
States With Age Restriction On OTC DXM Sales Number 17 – And Counting
Pennsylvania is 17th US state to limit sales of dextromethorphan OTCs to consumers 18 and older because teenagers' abuse of the ingredient for intoxicating effect remains a common problem.